Terra Sigillata

menu navigation

accounts: Terra Sigillata

  1. Bluenote
    17 November 2010 • 10:51 AM

    “The report was on the ROCKET AF trial where 14,264 patients with atrial fibrillation unrelated the heart valve disease were enrolled to compare the efficacy and side effect profile of warfarin relative to rivaroxaban (Xarelto, Bayer/J&J), a once-daily, oral inhibitor of Factor Xa (part of a complex that converts prothrombin to the endogenous coagulation protein, thrombin).”

    WTF! Why can’t professional journalist proofread? Just because it’s a blog doesn’t mean you don’t have to make sure it makes sense and the grammer is correct.

  2. David Kroll
    17 November 2010 • 2:40 PM

    Indeed, it may not have been the most concise sentence I’ve written. However, you might care to examine your own writing first, dear commenter.

  3. leigh
    17 November 2010 • 11:08 PM

    oh, this brings me back a few years to my own work on serpins and the clotting cascade.

  4. David Kroll
    17 November 2010 • 11:12 PM

    A bit of serendipity today on warfarin interactions, this time with herbal medicine supplements:

    http://www.latimes.com/health/boostershots/la-heb-warfarin-and-supplements,0,7455597.story

  5. JJM
    18 November 2010 • 11:30 AM

    Here is more http://www.sciencebasedmedicine.org/?p=8212

  6. Apixaban trial halted, eight others continue | Terra Sigillata
    19 November 2010 • 6:46 AM

    [...] writing this week about the new, direct-acting antithrombotic drugs that threaten to replace warfarin comes news that [...]

  7. Joe Reynolds MD
    7 January 2011 • 11:27 AM

    Interesting development in deciding on a porcine aortic vale or a metal one. So a new antithromboitc other than coumadin and with less side effects makes it an easier choice for a metal valve, if indeed the Pradexa can be used here.

iPad Theme

Leave A Comment

Cancel